ロード中...
The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
Systemic mastocytosis is a complex disease defined by abnormal growth and accumulation of neoplastic mast cells in various organs. Most patients exhibit a D816V-mutated variant of KIT, which confers resistance against imatinib. Clinical problems in systemic mastocytosis arise from mediator-related s...
保存先:
| 出版年: | Haematologica |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Ferrata Storti Foundation
2018
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5927976/ https://ncbi.nlm.nih.gov/pubmed/29439183 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.179895 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|